Pubblicazioni

• Apparently isolated CNS involvement in Erdheim-Chester disease: Case report
• Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
• Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
• The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire
• "Borderline" idiopathic CD4+ T-cell lymphocytopenia presenting with atypical progressive multifocal leukoencephalopathy
• Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis
• Therapeutic Plasmapheresis: A Revision of Literature
• MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis
• Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
• Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
• Disability assessment using Google Maps
• Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy
• Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue
• NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab
• Correction to: Disability assessment using Google Maps
• Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis
• Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)
• Identifying Cladribine prescription pattern in MS: an Italian multicentre study
• Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study
• COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
• Signs and symptoms of COVID-19 in patients with multiple sclerosis
• A real-world study of alemtuzumab in a cohort of Italian patients
• Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
• Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case-control study
• Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
• SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
• Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
• Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis
• Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
• The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis
• Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
• Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
• Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
• Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study
• Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis
• Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
• Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis
• The multidimensional assessment of body representation and interoception in multiple sclerosis
• Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
• Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
• Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response
• MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
• Switch from fingolimod to ozanimod for safety or intolerance reasons
• Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis
• Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
• Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
• Integrated Cognitive and Neuromotor Rehabilitation in Multiple Sclerosis: A Pragmatic Study
• COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients
• Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study
• The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests
• Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report
• Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease
• Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease
• Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis
• Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery
• Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity
• CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
• Fingolimod reduces the clinical expression of active demyelinating lesions in MS
• No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
• Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries
• Multiple Sclerosis Progression and Relapse Activity in Children
• Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis
• [Registers as central real world data source: the experience of the Italian Multiple Sclerosis and Related Disorders Register]
• Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis
• Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study
• Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
• Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression
• Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry
• Multiple sclerosis from onset to secondary progression: a 30-year Italian register study
• Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis
• Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective
• A narrative review of genetic and environmental factors and risk for multiple sclerosis. The design of the Italian multicentric PEDIGREE study
• Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis
• Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
• Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
• Prognostic indicators in pediatric clinically isolated syndrome
• Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis
• Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors
• Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
• Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
• Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
• Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register
• Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
• Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
• Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
• Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
• Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
• Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register
• Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project
• PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
• Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies
• Clinical and Genetic Heterogeneity in a Large Family with Pseudoxanthoma Elasticum: MTHFR and SERPINE1 Variants as Possible Disease Modifiers in Developing Ischemic Stroke
• Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study
• A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations
• Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register
• Normative values of the brief international cognitive assessment for multiple sclerosis (BICAMS) in an Italian young adolescent population: the influence of age, sex, and education
• Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy